Figure 2.

Luteolin inhibits cell cycle progression in breast cancer cells. (A) MDA-MB-231 cells were treated with 0, 10 or 30 µM luteolin and analyzed by flow cytometry to determine the distribution of cells in different phases of the cell cycle. (B) Histogram representing the mean value of three independent experiments. MDA-MB-231 cells accumulated in S phase following luteolin treatment. (C) Total protein was isolated from control and luteolin-treated MDA-MB-231 cells, and subjected to immunoblotting of p21, Survivin and cyclin D1 proteins. Membranes were stripped and re-probed with anti-GAPDH antibody to ensure equal protein loading. p21 was upregulated, whereas Survivin and cyclin D1 were downregulated in MDA-MB-231 cell in a dose-dependent manner. *P<0.05 vs. the control group (0 µM luteolin); #P<0.05 vs. the 10 µM luteolin group.